Navigation Links
Watson Launches Generic FEMCON(R) Fe
Date:9/26/2011

PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets (Chewable), 75 mg, a generic version of Warner Chilcott's FEMCON(R) Fe. Watson began shipping the product today. FEMCON(R) Fe is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

For the most recent twelve months ending July 31, 2011, FEMCON(R) Fe had sales of approximately $35 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended June 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

FEMCON(R) Fe is a registered trademark of Warner Chilcott Company, Inc.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
2. Watson to Present at the Jefferies 2011 Global Healthcare Conference
3. Watson Confirms Amphastar Patent Lawsuit
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference
6. Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference
7. Watsons Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS
8. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
9. Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
10. Watson Confirms JALYN™ Patent Challenge
11. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... Therapix Biosciences Ltd. (Nasdaq: TRPX), a ... development of cannabinoid-based drugs, today announced that the ... three upcoming scientific and investor conferences in June: ... ... Wednesday, June 7 ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
(Date:5/18/2017)... -- Two Bayer U.S. Pharmaceutical leaders received top awards from ... th Woman of the Year event ... mission of furthering the advancement and impact of women ... Powell-Steffen , senior director of brand activation and inside ... Howe , a regional business manager for New England ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... ... essential, and two new videos highlight the importance of correctly using a meat ... Ph.D., who has done extensive research on consumer food safety habits. Dr. Bruhn ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
(Date:6/23/2017)... Dunmore, PA (PRWEB) , ... June 23, 2017 ... ... provides insurance management, financial planning, and related services to families and business owners ... for a charity drive to benefit senior citizens in the area. , Meals ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an ... with access to asset protection and financial planning services, is teaming up with ... the lives of children with cancer and other chronic diseases. , The For ...
(Date:6/22/2017)... ... June 22, 2017 , ... Groove Ring is excited to announce ... high performance silicon wedding bands and all-purpose rings. Whether you’re an athlete, adventurer, professional, ... designed just for you. , From the rock face to the auto shop, Groove ...
Breaking Medicine News(10 mins):